is known as chloramphenicol. They both differ from their predecessors in that they are best administered by the mouth. It is not clear that absorption from the alimentary tract is complete, but it is sufficient, and adequate levels are maintained in the blood for several hours after a single dose. This is fortunate, since chloromycetin is too insoluble and aureomycin in its usual form too acid for solutions to be injected intramuscularly. Aureomycin can, if necessary, be injected intravenously in a large volume of solvent: it should never be injected intrathecally and this is, in any case, unnecessary since it reaches the cerebrospinal fluid via the blood. For the same reasons local application has been little practised, although aureomycin borate has been successfully used in treating conjunctivitis (Braley and Sanders, 1948) .
No dangerous toxic effects have been noted from either drug. Both have a very bitter taste, and it is consequently difficult to get children to take them. Aureomycin tends to cause nausea and vomiting, and chloromycetin may produce anorexia and dryness of the mouth.
Whereas penicillin and streptomycin are both bactericidal, the former killing bacteria with moderate rapidity at its optimum concentration and the latter behaving like an ordinary germicide and killing more and more rapidly the higher the concentration employed, aureomycin and chloromycetin are both purely bacteriostatic.
Theoretically this might be expected to mean that they should be administered for rather longer periods in conditions, such as urinary tract infections, in which any of the four may be indicated, according to the nature of the infection, and the circumstances are favourable for bactericidal effect.
These two new drugs have brought within the scope of effective chemotherapy a wide range of infections for which there was previously no dependable specific treatment. Perhaps the most important of these is typhus. Chloromycetin has an astonishing effect in scrub typhus (Lewthwaite, Chloromycetin in typhus and typhoid, Proc. R. Soc. Med., 1950, 43, Sect. Exper. Med., in Press) , and it seems that all rickettsial infections respond to one or other of these two drugs, although their relative merits are not yet fully assessed (Woodward, 1949) . It is equally remarkable that they have an action on a few viruses, notably those of lymphogranuloma venereum (Wright et al., 1948) , psittacosis, and primary atypical pneumonia (Kneeland et al., 1949; Finland et al., 1949b) . Aureomycin has been chiefly used for these three diseases, and the usefulness of chloromycetin is less well established: to judge by the experimental results of Eaton (1950), chloromycetin would not be expected to be so useful in the last-named. According to Dawson and Simon (1949) , aureomycin also has an effect on herpes zoster: this requires confirmation. Chloromycetin is apparently without influence on this condition.
Chloromycetin is reported to be effective in trachoma. It must be understood that neither drug has the slightest action on many other important viruses, notably those of influenza and poliomyelitis.
Among bacterial infections also there are a number in which the two new drugs are superior to anything we have hitherto possessed. A general idea of this activity against the main bacterial species canbe gained from Fig. I which shows the concentrations in ,Lg per ml. inhibiting their growth as compared with that of penicillin. These are only approximate, since reported findings vary with the technique used, and in any case there is some strain variation. Two important general tendencies emerge from such a tabulation. It is clear that aureomycin has the greater activity against Gram-positive cocci, and this is borne out by clinical experience. To take two examples, it is a valuable standby in penicillin-resistant staphylococcal infections (Nichols and Needham, 1949) , and it is effective in pneumococcal pneumonia (Finland et al., 1949a) : indeed it is effective in every kind of pneumonia including all common 690 42 bacterial forms and those due to viruses, and has thus been recommended as the safest drug to use when laboratory facilities are lacking (Herrell, 1949) .
Chloromycetin, on the other hand, has an evidently superior activity-against Gram-negative bacilli generally, and much the most important practical application of this is in the treatment of typhoid fever. Neither drug has a useful action on Ps. pyocyanea, and Proteus tends to be resistant, although rather less so. Both are active in vitro against the Brucellas, and this action has been confirmed clinically, the remarkably curative effect of aureomycin in undulant fever due to either Br. melitensis and his colleagues and confirmed on a smaller scale in this country. Chloromycetin has also been used successfully but not yet on a sufficient scale to assess its relative merit.
Both drugs will cure gonorrhoea, and aureomycin has also an effect in non-specific urethritis (Willcox and Findlay, 1949) and in syphilis (O'Leary et a!., 1948 (O'Leary et a!., , 1949 , although its place in the treatment of this disease is not yet defined.
The main indications for both drugs have been mentioned. There are others which remain to be fully explored. These include among specific infections, whooping-cough and intestinal infections other than enteric fever, with particular reference to the possibility of abolishing the carrier state as well as alleviating the acute stage. Among less well-defined conditions are septicxemia, meningitis, pulmonary suppur'ation and urinary tract infections in which Gram-negative organisms are concerned. Here the problem is to, assess the relative merits 'of the two new drugs and of streptomycin.
In any such studies we have a duty to remember that whereas streptomycin and chloromycetin are both manufactured in this country, aureomycin has all to be paid for in dollars. Hence a particular interest we have is to determine how far one of the other drugs can be made to serve in its place.
Dr. John Crofton, Postgraduate Medical School of London.
The emergence of streptomycin-resistant tubercle bacilli is the outstanding disadvantage of this drug in tuberculosis. It is now usually accepted that a minute proportion of resistant bacteria is present in cultures obtained from a patient before treatment. It seems likely that these resistant forms arise from the streptomycin-sensitive bacteria by a genetic change which can be regarded as a mutation. There are two main reasons for suggesting this. Firstly. the resistant bacteria breed true; reversion to sensitivity is very unusual if it occurs at all. Secondly, there is no increase of resistant bacteria in the presence of streptomycin unless the bacteria are in a medium which enables them to multiply. During treatment of a case of pulmonary tuberculosis with streptomycin the proportion of resistant tubercle bacilli increases. When the proportion of resistant to sensitive bacilli is roughly 1/50 to 1/2500 the culture shows as resistant in the ordinary routine tests when read at ten days (Mitchison, 1950a) . Eventually the whole population of tubercle bacilli in the patient may become streptomycin resistant (Pyle, 1947; Mitchison, 1950b) . In Gram-negative bacteria the mutation rate of sensitive to resistant forms is said to vary from species to species and there is said to be an inverse relationship between this rate and susceptibility to streptomycin in vitro and in vivo (Alexander et al., 1949) . Whether the mutation rate varies from strain to strain of tubercle bacilli is uncertain though there is a little evidence to suggest that the rate may differ in strains derived from different patients, and that this may be related to the ultimate emergence of resistant tubercle bacilli as measured in the routine tests for streptomycin sensitivity. But bacteria which have become streptomycin resistant may become so in varying degrees and the proportions of bacilli in pre-treatment cultures with different levels of streptomycin resistance would obviously be of great interest. The evidence on the point is tenuous (Yegian and Vanderlinde, 1948; Meads and Haslam, 1949) , but such as it is it suggests that slightly resistant forms are more frequent than moderately or highly resistant, but that moderately and highly resistant forms are about equal in frequency.
The genetic basis of mutation to various degrees of streptomycin resistance is uncertain, but there is enough evidence to make some suggestions. It is worth recalling Demerec's theory (Demerec, 1948) of the genetic basis of acquired penicillin resistance (Fig. 1 ). If sensitive bacteria are cultured into a series of tubes containing ascending concentrations of penicillin they can only be rendered highly resistant by a series of subcultures, subculturing on each occasion from the highest tube in which there is growth. By this means the bacteria become slightly more penicillin resistant at each subculture and eventually reach a high grade of resistance. Demerec suggests that there are a series of genes of roughly equal potency, a mutation in any one of which is capable of giving rise to a slight increase in penicillin resistance. The chances are that mutations in significant numbers will occur in only one gene at each subculture, so that at each successive culture organisms emerge with slightly increased resistance. If the subculture is made from the tube with the highest concentration of penicillin, then the initial population of bacteria will have one mutated gene so that in the next subculture there is a good chance of a second gene mutating, giving a further rise in resistance. And so on. If this experiment is repeated with streptomycin the results may be very different (Fig. 2) . In any subculture there may be sudden leaps of resistance to high levels. It is suggested that the facts are consistent with resistance being due to a number of genes of different degrees of potency. A mutation in some genes will produce bacteria of low resistance, a mutation in others of moderate, and yet in others of very high degrees ofresistance. The low-potency genes are probably more numerous, and therefore more likely to mutate and produce bacteria with low degrees of streptomycin resistance, but every now and then a mutation will occur in a high-potency gene, with the consequent emergence of highly resistant bacteria. Such a mechanism would account for the suggested distribution of bacteria with different degrees of resistance in pre-treatment cultures. It would also imply that the larger the bacterial population and the more rapidly it is multiplying the more likely are the rare mutations to highly resistant forms to occur. It is theoretically possible that exposure to streptomycin might increase the general mutation rate in a nonspecific manner, just as unfavourable conditions increase the mutation rate in plants.
In both the series of cases of pulmonary tuberculosis treated with streptomycin with which I have been associated there has been a clear relation between the time at which streptomycin-resistant tubercle bacilli were first isolated and the degree of streptomycin resistance which was eventually attained (Crofton and Mitchison, 1948; Bignall et al., 1950) . The earlier that resistant tubercle bacilli were isolated after starting treatment the more highly.resistant these bacilli eventually became. This was not because they had longer to become highly resistant, for the organisms attained SEPT. MED. 2 their final level of resistance relatively rapidly. This finding again is consistent with the conception that the more rapid the multiplication of the bacilli and the larger the bacterial population the more likely are mutations to occur in highly potent genes. In consequence the more likely are highly resistant forms to emerge, and the more likely are they to emerge early. Evidence is accumulating that clinical factors may be correlated with emergence of streptomycin-resistant strains of tubercle bacilli. In cases in which the radiograph shows cavitation, there is a much greater likelihood of streptomycin-resistant tubercle bacilli emerging than when no cavity is demonstrable. Fig. 3 is derived from several American series (Mitchell, 1949; Howard et al., 1949; Howlett et al., 1949) and speaks for itself. In a recent series (Bignall et al., 1950) we have found a correlation between the degree of confluence of shadows in the radiograph and the time of emergence of streptomycin-resistant organisms. The more confluent the shadows the earlier resistant forms emerge. It is worth stopping a moment to consider whether the actual physical condition in the lung, as instanced by cavitation and confluence, may directly influence the emergence of tubercle bacilli (Fig. 4) 4. -Possible mechanism by which physical cases from which streptomycin-resistant tubercle conditions in the lung might affect the emergence bacilli were isolated in those with and without of streptomycin-resistant tubercle bacilli. The large cavitation or caseation on the radiograph. The circle represents an area into which streptomycin figures are derived from three different series penetrates poorly. (Mitchell, 1949; Howard et al., 1949; and Howlett et al., 1949) , in which the criteria were slightly different. poorly into certain areas of the lung it may be that in the centre of these areas there is a rapid multiplication of tubercle bacilli with a consequent production by mutation of streptomycin-resistant forms. As forms of higher and higher degrees of streptomycin resistance emerge they will become capable of growing out along the gradient of increasing streptomycin concentration until eventually they may become capable of growing in contact with full concentrations of streptomycin.
We have found an indefinite but slightly suggestive correlation between the general clinical severity of the case and the emergence of resistant organisms (Bignall et al., 1950) . There are many exceptions to this trend but often very ill patients do produce tubercle bacilli with high degrees of streptomycin resistance and patients who are initially relatively well are a little less likely to do so. It seems possible that both these factors and the physical condition in the lung may be related to the emergence of streptomycin-resistant bacteria only in so far as they reflect the size of the bacterial population and the rate at which it is multiplying.
We have found that if routine examinations of the sputum are made in a patient with pulmonary tuberculosis under treatment with streptomycin there is usually an initial drop in positivity followed by a later rise (Crofton and Mitchison, 1948; Bignall et al., 1950) . If this drop does not occur it is nearly always an indication that highly streptomycin-resistant tubercle bacilli will emerge. But the converse is not true, as resistant organisms may emerge even though there is a significant drop in positivity. After the drop in positivity, unless the patient becomes permanently sputum negative, there is usually a later rise. When this has occurred it is found that streptomycin-resistant forms have emerged. It is interesting that this later rise will occur even when the tubercle bacilli have shown only a very slight increase in streptomycin resistance. This suggests that even low degrees of resistance may be of some clinical importance. But they are probably of less clinical importance than high degrees of resistance, because we have found that eventual sputum conversion is much commoner in those patients from whom only tubercle bacilli of low degrees of streptomycin resistance have been isolated.
Two main methods have been employed in an attempt to prevent the emergence of streptomycin-resistant tubercle bacilli. The first method is to give streptomycin intermittently. We have tried giving it in alternate weeks or alternate months with no success. It seems possible that giving 1 gramme every third day may delay the. emergence of streptomycin resistance in a proportion of cases (Tucker, 1949) but further work needs to be done on this. The second method is by combining other drugs with streptomycin. So far the only drug which appears to be of indubitable value in this respect is para-aminosalicylic acid (Medical Research Council, 1949) .
non-tuberculous infections have become more restricted, but at the present time there is insufficient information to assess the relative merits of the three antibiotics. The disadvantages of streptomycin compared with the new drugs are the necessity for treatment by injection, its toxic effects and the development of resistance to streptomycin by many bacteria. Streptomycin finds its chief use in infections due to Gramnegative bacilli and penicillin-resistant cocci. It is still probably the drug of-choice in H. influenza meningitis in combination with sulphadiazine. It gives favourable results in other forms of penicillin-resistant pyogenic meningitis, particularly those cases developing after brain operations. In. penicillin-resistant bacterial endocarditis streptomycin is ineffective alone and should probably be used in combination with other antibiotics. In septicxmia without endocarditis, especially due to B. coli or Ps. pyocyanea it is usually effective. In the large field of urinary tract infections it is likely that the newer antibiotics will supersede streptomycin owing to the frequent development of resistance to the latter. Streptomycin may still be the treatment of choice, however, in proteus and pyocyaneus infections. Results of streptomycin therapy are disappointing in respiratory tract infections although in Friedlander or H. influenza, infections it is still probably the most potent antibiotic. Aureomycin should always be employed in penicillin-resistant staphylococcal infections. In view of its toxicity, streptomycin should never be used without expert bacteriological control and the closest co-operation between clinician and bacteriologist is essential before and after instituting treatment with the drug.
